Single Pill Lowers Blood Pressure More Than Usual Care
A four-year randomized trial in Colombia and Jamaica found a polypill regimen outperformed multi-pill standard care for uncontrolled hypertension.
Updated on Nov. 9, 2026 in Heart Disease
Live Poll
Would you ask your doctor about a single-pill option for high blood pressure?
A single-pill antihypertensive combination lowered blood pressure more than multi-pill usual care among 1,706 patients with uncontrolled hypertension in the CATCH trial, conducted at 40 primary care clinics in Colombia and Jamaica. Findings were presented at the AHA Scientific Sessions and published in JAMA.
Why it matters
Blood pressure control remains poor globally, with only 22.5% of U.S. hypertension patients controlled and 13.6% in low- and middle-income countries. The results add trial evidence supporting single-pill combination therapy as a way to improve control.
In the CATCH trial, about 19 points of systolic reduction occurred in the single-pill group versus 9 points in usual care after 18 months, against a 22.5% U.S. control rate and 13.6% control rate in low- and middle-income countries. Whether these blood pressure gains translate into fewer heart attacks or strokes remains unknown.
The players
American Heart Association
The American Heart Association is a leading U.S. nonprofit focused on cardiovascular health research, whose annual Scientific Sessions showcase major clinical studies.
JAMA
JAMA is a peer-reviewed medical journal published by the American Medical Association that publishes major clinical trial research.
The details
Standard care clinics started patients on one antihypertensive drug and added medications over time, while intervention clinics gave a polypill combining two or three drugs. Intervention patients also received nurse-taught home blood pressure monitoring and health coach training on adherence.
Timeline
Trial conducted over a four-year period in Colombia and Jamaica.
Blood pressure results were measured at 18 months after trial start.
Six months after the trial ended, 75% of intervention patients were still on single-pill treatment.
Findings were presented at the AHA Scientific Sessions and published in JAMA on November 8, 2026.
Big Picture
The 2017 ACC/AHA hypertension guideline set a 130/80 mm Hg target, yet control rates remain low, and the CATCH results add trial evidence for single-pill combination therapy as a way to close that gap. Current guidelines already recommend single-pill combinations, but this trial is among the evidence supporting that recommendation in real clinic settings.
Patients with uncontrolled hypertension may ask their clinicians whether a single-pill combination could simplify a multi-drug regimen. The trial suggests home blood pressure monitoring and adherence coaching can help people reach their blood pressure goals.
The takeaway
Simplifying blood pressure treatment into a single daily pill, paired with home monitoring and coaching, may help more people reach their goals. Talk with a clinician about whether a combination regimen fits your treatment plan.
Further reading
For broader context on blood pressure and cardiovascular risk, explore Heart Disease.
More information
Read the full JAMA journal article on the CATCH single-pill hypertension trial.
Source note: This article includes information reported by News-Medical.
Live Poll
Would you ask your doctor about a single-pill option for high blood pressure?
